NCT02617758View on ClinicalTrials.gov

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Healthy
Interventions
DRUG

Fentanyl

Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.

DRUG

Fentanyl

Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.

Trial Locations (1)

Unknown

Cypress

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02617758 - Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants | Biotech Hunter | Biotech Hunter